Top 20 biopharma market caps fall 5.7% amid industry challenges
Bristol Myers Squibb saw the largest decline at -22.9%, with Regeneron at -18.7% and Sanofi at -13.8%.
Comment & Opinion
Cystic fibrosis market forecast to reach $16.0bn by 2034 in the 7MM
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri
Morocco’s sweeping pharmaceutical pricing reform
ESC 2025: Higher leg muscle scores reduce cardiovascular risk independent of BMI
Four drugs race for first bispecific ADC approval
2024 saw growth recovery for almost all top biopharma companies
AI is improving idiopathic pulmonary fibrosis care
